Suma Krishnan

Company: Krystal Biotech

Job title: Chief Executive Officer

Seminars:

Targeting Serious Rare Disease with Gene Therapy 1:30 pm

Outlining the rationale for targeting Netherton Syndrome and MOA of serine peptidase inhibitor kazal type 5 Discussing concurrent challenges in the rare disease clinical trial space across dystrophic epidermolysis bullosa, ARC1, and Netherton Syndrome Highlighting upcoming late-stage milestonesRead more

day: Day 2 PM - Track B